Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BLPH Stock Summary
Top 10 Correlated ETFs
BLPH
In the News

Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going
Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

How to Find Cheap Penny Stocks to Make Money Trading
Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks Exploding After News This Week
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size
Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon's Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

Bellerophon Therapeutics Stock (BLPH): Why The Price Jumped
The stock price of Bellerophon Therapeutics Inc (NASDAQ: BLPH) increased by 34.6% in the previous trading session. This is why it happened.

These Biotech Penny Stocks Exploded Today, Here's Why
Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Bellerophon Therapeutics (BLPH) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.
BLPH Financial details
BLPH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | -3.17 | 0 | |
Operating cash flow per share | -6.06 | -4.05 | -2.87 | -2.55 | -2.4 | |
Free cash flow per share | -6.06 | -4.05 | -2.87 | -2.55 | -2.4 | |
Cash per share | 12.25 | 4.35 | 2.19 | 6.1 | 2.6 | |
Book value per share | -1 | 1.01 | 0.8 | 4.91 | 2.28 | |
Tangible book value per share | -1 | 1.01 | 0.8 | 4.91 | 2.28 | |
Share holders equity per share | -1 | 1.01 | 0.8 | 4.91 | 2.28 | |
Interest debt per share | 0 | 0 | 0.15 | 0.12 | 0.1 | |
Market cap | 100.49M | 46.04M | 23.62M | 52.01M | 29.46M | |
Enterprise value | 71.67M | 29.39M | 16.07M | 6.11M | 5.68M | |
P/E ratio | 0 | 0 | 0 | -2.1 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -6.38 | -2.97 | -1.83 | -2.62 | -1.29 | |
PFCF ratio | -6.38 | -2.97 | -1.83 | -2.62 | -1.29 | |
P/B Ratio | -38.74 | 11.94 | 6.58 | 1.36 | 1.36 | |
PTB ratio | -38.74 | 11.94 | 6.58 | 1.36 | 1.36 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | -0.23 | -0.28 | |
EV to operating cash flow | -4.55 | -1.9 | -1.24 | -0.31 | -0.25 | |
EV to free cash flow | -4.55 | -1.9 | -1.24 | -0.31 | -0.25 | |
Earnings yield | 0 | 0 | 0 | -0.48 | 0 | |
Free cash flow yield | -0.16 | -0.34 | -0.55 | -0.38 | -0.77 | |
Debt to equity | -15.19 | 3.76 | 2.65 | 0.31 | 0.24 | |
Debt to assets | 1.07 | 0.79 | 0.73 | 0.24 | 0.2 | |
Net debt to EBITDA | 0 | 0 | 0 | 1.73 | 1.19 | |
Current ratio | 5.03 | 2.31 | 1.37 | 4.61 | 5.04 | |
Interest coverage | 0 | 0 | 0 | -105.1 | -4.03K | |
Income quality | 0 | 0 | 0 | 0.8 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 18.71 | 0 | |
ROIC | 0 | 0 | 0 | 0.5 | 0 | |
Return on tangible assets | 0 | 0 | 0 | -0.49 | 0 | |
Graham Net | -2.92 | 0.56 | 0.08 | 4.56 | 2.05 | |
Working capital | 28.5M | 9.86M | 2.8M | 37.65M | 20.41M | |
Tangible asset value | -2.59M | 3.86M | 3.59M | 38.25M | 21.62M | |
Net current asset value | -3.82M | 2.89M | 865K | 36.09M | 20.2M | |
Invested capital | 0 | 0 | 0.18 | 0.02 | 0.04 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.33M | 3.3M | 2.93M | 3.42M | 2.46M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | -0.65 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.49 | 0 | -0.59 | -0.43 | -0.53 | |
Operating cash flow per share | -0.59 | -0.42 | -0.5 | -0.38 | -0.52 | |
Free cash flow per share | -0.59 | -0.42 | -0.5 | -0.38 | -0.52 | |
Cash per share | 3.02 | 2.6 | 2.1 | 1.71 | 1.19 | |
Book value per share | 2.71 | 2.27 | 1.69 | 1.29 | 0.78 | |
Tangible book value per share | 2.71 | 2.27 | 1.69 | 1.29 | 0.78 | |
Share holders equity per share | 2.71 | 2.27 | 1.69 | 1.29 | 0.78 | |
Interest debt per share | 0.12 | 0.1 | 0.08 | 0.06 | 0.05 | |
Market cap | 38.6M | 29.47M | 22.53M | 11.74M | 10.4M | |
Enterprise value | 11.02M | 5.69M | 3.3M | -4M | -516.46K | |
P/E ratio | -2.08 | 0 | -1 | -0.72 | -0.51 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -6.91 | -7.41 | -4.76 | -3.2 | -2.08 | |
PFCF ratio | -6.91 | -7.41 | -4.76 | -3.2 | -2.08 | |
P/B Ratio | 1.5 | 1.36 | 1.39 | 0.96 | 1.4 | |
PTB ratio | 1.5 | 1.36 | 1.39 | 0.96 | 1.4 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.39 | -1.34 | -0.59 | 0.62 | 0.1 | |
EV to operating cash flow | -1.97 | -1.43 | -0.7 | 1.09 | 0.1 | |
EV to free cash flow | -1.97 | -1.43 | -0.7 | 1.09 | 0.1 | |
Earnings yield | -0.12 | 0 | -0.25 | -0.35 | -0.49 | |
Free cash flow yield | -0.14 | -0.13 | -0.21 | -0.31 | -0.48 | |
Debt to equity | 0.21 | 0.24 | 0.34 | 0.44 | 0.7 | |
Debt to assets | 0.18 | 0.2 | 0.26 | 0.31 | 0.41 | |
Net debt to EBITDA | 5.98 | 5.59 | 3.42 | 2.43 | 2.18 | |
Current ratio | 5.8 | 5.04 | 3.69 | 3.12 | 2.33 | |
Interest coverage | 0 | -854.6 | -5.64K | -344.26 | -108.85 | |
Income quality | 1.21 | 0 | 0.84 | 0.89 | 0.99 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.45 | 0 | 4.75 | 3.53 | 3.05 | |
ROIC | 0.18 | 0.14 | 0.28 | 0.24 | 0.44 | |
Return on tangible assets | -0.15 | 0 | -0.26 | -0.23 | -0.4 | |
Graham Net | 2.44 | 2.05 | 1.51 | 1.14 | 0.64 | |
Working capital | 24.59M | 20.41M | 14.95M | 11.54M | 6.88M | |
Tangible asset value | 25.79M | 21.62M | 16.17M | 12.28M | 7.43M | |
Net current asset value | 24.19M | 20.2M | 14.94M | 11.54M | 6.88M | |
Invested capital | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.88M | 1.24M | 1.69M | 2.1M | 1.77M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.18 | 0 | -0.35 | -0.33 | -0.68 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BLPH Frequently Asked Questions
What is Bellerophon Therapeutics, Inc. stock symbol ?
Bellerophon Therapeutics, Inc. is a US stock , located in Warren of Nj and trading under the symbol BLPH
What is Bellerophon Therapeutics, Inc. stock quote today ?
Bellerophon Therapeutics, Inc. stock price is $7.19 today.
Is Bellerophon Therapeutics, Inc. stock public?
Yes, Bellerophon Therapeutics, Inc. is a publicly traded company.